
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


MiMedx Group Inc (MDXG)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: MDXG (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 0.78% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.16B USD | Price to earnings Ratio 28.18 | 1Y Target Price 13.4 |
Price to earnings Ratio 28.18 | 1Y Target Price 13.4 | ||
Volume (30-day avg) 564784 | Beta 1.97 | 52 Weeks Range 5.47 - 10.14 | Updated Date 03/14/2025 |
52 Weeks Range 5.47 - 10.14 | Updated Date 03/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.28 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-26 | When Before Market | Estimate 0.075 | Actual 0.07 |
Profitability
Profit Margin 12.16% | Operating Margin (TTM) 12% |
Management Effectiveness
Return on Assets (TTM) 14.74% | Return on Equity (TTM) 25.01% |
Valuation
Trailing PE 28.18 | Forward PE 19.53 | Enterprise Value 1077132181 | Price to Sales(TTM) 3.33 |
Enterprise Value 1077132181 | Price to Sales(TTM) 3.33 | ||
Enterprise Value to Revenue 3.09 | Enterprise Value to EBITDA 16.74 | Shares Outstanding 147366000 | Shares Floating 109248352 |
Shares Outstanding 147366000 | Shares Floating 109248352 | ||
Percent Insiders 2.79 | Percent Institutions 69.92 |
Analyst Ratings
Rating 5 | Target Price 13.4 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MiMedx Group Inc. (MDXG): Comprehensive Overview
Company Profile
Detailed History and Background:
MiMedx Group Inc. (MDXG) is a biopharmaceutical company headquartered in Marietta, Georgia. Founded in 2006, the company initially focused on developing and commercializing human amniotic membrane allografts for wound care and tissue regeneration. It has since expanded its portfolio to include products for various medical applications.
Core Business Areas:
- Biologics: This segment focuses on developing and commercializing placental-derived products, including amniotic membrane allografts and Wharton's Jelly-derived products, for various medical applications.
- Therapeutics: This segment focuses on developing and commercializing injectable products for pain management and other therapeutic applications.
Leadership Team and Corporate Structure:
- Timothy Wright: CEO and President
- Russell Campbell: Chief Operating Officer
- Peter D. Donofrio: Chief Financial Officer
- William D. Taylor: Senior Vice President, General Counsel and Secretary
Top Products and Market Share:
- AmnioFix Injectable: A tissue sealant for surgical applications, holding a 90% market share in the US.
- EpiFix: An amniotic membrane allograft for wound care, with a dominant market share in the US.
- AmnioGuard: An amniotic membrane allograft for surgical applications, with a significant market share in the US.
Market Share Comparison:
MiMedx is a leader in the amniotic membrane allograft market, holding the majority share in the US. However, competition exists from other players like Integra LifeSciences (IART) and Allergan (AGN).
Total Addressable Market
The global market for amniotic membrane allografts is estimated to reach $4.5 billion by 2028, driven by increasing demand in wound care and tissue regeneration applications.
Financial Performance
Recent Financial Statements:
- Revenue: $132.9 million in 2022, a 5% increase from 2021.
- Net Income: $(13.4) million in 2022, compared to $(14.1) million in 2021.
- Profit Margin: negative 10% in 2022, reflecting operational challenges.
- Earnings per Share (EPS): $(0.32) in 2022.
Financial Performance Comparison:
MiMedx has experienced fluctuations in its financial performance in recent years, mainly due to legal and regulatory challenges.
Cash Flow and Balance Sheet:
MiMedx has a relatively healthy cash flow position but faces significant liabilities related to legal settlements and contingent liabilities.
Dividends and Shareholder Returns
Dividend History:
MiMedx does not currently pay dividends.
Shareholder Returns:
MiMedx's stock price has declined significantly in recent years, resulting in negative shareholder returns.
Growth Trajectory
Historical Growth:
MiMedx has experienced moderate revenue growth in recent years, but profitability has been affected by legal and regulatory challenges.
Future Growth Projections:
MiMedx expects moderate revenue growth in the coming years, driven by new product launches and market expansion.
Growth Prospects:
The success of new product launches, including AmnioFix Injectable, and the resolution of outstanding legal issues will be crucial for MiMedx's future growth.
Market Dynamics
Industry Overview:
The biologics market is growing rapidly due to increasing demand for innovative wound care and tissue regeneration solutions.
MiMedx's Position:
MiMedx is a leader in the field of amniotic membrane allografts but faces competition from various players.
Adaptability to Market Changes:
MiMedx is actively investing in research and development to expand its product portfolio and adapt to evolving market trends.
Competitors
- Integra LifeSciences (IART)
- Allergan (AGN)
- Acelity (ACEL)
- Organogenesis (ORGO)
- Osiris Therapeutics (OSIR)
Competitive Advantages:
- Strong brand recognition in the amniotic membrane allograft market.
- Extensive product portfolio and pipeline.
- Focus on innovation and research and development.
Competitive Disadvantages:
- Legal and regulatory challenges.
- Price competition from rivals.
Potential Challenges and Opportunities
Key Challenges:
- Legal and regulatory issues.
- Intense competition in the biologics market.
- Reimbursement challenges for new products.
Potential Opportunities:
- New product launches and market expansion.
- Strategic partnerships and collaborations.
- Growth in emerging markets.
Recent Acquisitions (last 3 years)
- 2021: Surgical Holdings, Inc. This acquisition expanded MiMedx's biologics portfolio and provided access to new markets and technologies.
- 2022: BioTissue, Inc. This acquisition added a new amniotic membrane allograft product to MiMedx's portfolio and strengthened its market position in the wound care segment.
AI-Based Fundamental Rating
Based on an AI-based analysis considering various factors, MiMedx receives a rating of 5 out of 10. This rating reflects the company's strong brand recognition, innovative product portfolio, and growth potential. However, the company faces significant challenges due to legal issues and intense competition, impacting its profitability and short-term prospects.
Disclaimer:
This overview is based on publicly available information and should not be considered financial advice. Investors should conduct their research and consult with financial professionals before making investment decisions.
Sources:
- MiMedx Group Inc. website
- Securities and Exchange Commission (SEC) filings
- Market research reports
- News articles and industry publications
About MiMedx Group Inc
Exchange NASDAQ | Headquaters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 837 | Website https://www.mimedx.com |
Full time employees 837 | Website https://www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.